Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...

Indian drugmakers are preparing for the launch of copycat weight-loss drugs as the world moves towards the patent expiry of ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced the continuation of its ambitious 2024 share repurchase program, now initiating an additional buyback of up to DKK 3.14 billion.

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Asit, this week, competitor Novo Nordisk out with earnings and news that their blockbuster weight drug, Wegovy posted better ...

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...